Clinical Trial Update: Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing efficacy and safety of sugammadex dosed by actual body weight or ideal body weight for reversing neuromuscular blockade in morb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade Induction Reversal in Anesthesia

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neuromuscular Blockade | Phase 4 | Status: COMPLETED | Results posted: 2019-12-23